Total Hip Arthroplasty in Cirrhosis is Associated with Increased Complications during the Hospital Stay, Length of Stay, and Cost of Care: A Propensity Matched Database Study

Document Type : RESEARCH PAPER


1 Department of Orthopedic and Rehabilitation University of New Mexico, Raymond Murphy Medical Centre, USA

2 Virginia Common wealth University, Richmond, VA, USA

3 Department of Orthopedics, University of Texas, Southwestern, Dallas, Texas, USA


Objectives: The aim of the study is to evaluate the impact of cirrhosis on inpatient hospital complications and 
healthcare costs in elective Total Hip Arthroplasty (THA).
Methods: A 4-year retrospective analysis of the Nation Inpatient Sample (NIS) database, who underwent elective 
THA stratified by the presence or absence of cirrhosis was performed (2016-19). The records of specific 
postoperative complications, the cost of care (COC), and the length of stay (LOS) were evaluated by statistical 
Results: The NIS database identified 367,894 patients who underwent THA, of which 1,134 (0.3%) were cirrhotic. 
In the unmatched analysis, patients with cirrhosis showed significantly elevated rates (P< 0.05) of in-hospital 
complications compared to non-cirrhotic controls, including mortality (0.7% vs. 0.1%), acute renal failure (9.2% vs. 
2.5%), blood loss anemia (30.4% vs. 19.5%), pneumonia (1.1% vs. 0.3%), periprosthetic fracture (3% vs. 1.2%), 
dislocations (2.5% vs. 1.4%), infection (4.2% vs. 1%), wound dehiscence (0.8% vs. 0.1%) and blood transfusion 
(11.3% vs. 3.5%). After propensity matching, significantly higher rates of blood loss anemia (30.4% vs. 26.7%; 
P=0.05), periprosthetic dislocations (2.4% vs. 1%; P=0.008), and infections (4.2% vs. 2.7%, P=0.05) were seen in 
the cirrhotic cohort, while the rate of pulmonary embolism was significantly lower (0% vs. 0.8%, P=0.002), as was 
myocardial infarction (0.08% vs. 0.7%, P=0.017). Concerning LOS in the hospital, patients with cirrhosis stayed 
significantly longer in both the unmatched (4.2 vs. 2.3 days; P <0.001) and matched (4.2 vs. 3.68; P=0.016) controls. 
The average COC was greater in the cirrhotic group, with a mean value of $90,264 vs. $66,806.31 (P<0.001) in the 
unmatched and $90,624 vs. $80,676.87 (P=0.001) in the matched cohort.
Conclusion: Cirrhosis is associated with longer lengths of stay, higher hospital costs, and a greater risk of 
perioperative in-hospital complications such as blood loss anemia, dislocation, and infection after THA. This data 
could assist during preoperative patient counseling and improve the strategies for effectively utilizing the finite 
healthcare resources without compromising patient care and financial compensation from payers. 
 Level of evidence: IV


Main Subjects

1. Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. 
Underestimation of liver-related mortality in the United 
States. Gastroenterology. 2013; 145(2):375-382.e1-2. 
2. Scaglione S, Kliethermes S, Cao G, et al. The Epidemiology of 
Cirrhosis in the United States: A Population-based Study. J 
Clin Gastroenterol. 2015; 49(8):690-696. 
3. Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology 
of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol 
Hepatol. 2020; 18(12):2650-2666. 
4. Newman JM, Schiltz NK, Mudd CD, Szubski CR, Klika AK, 
Barsoum WK. Impact of Cirrhosis on Resource Use and 
Inpatient Complications in Patients Undergoing Total Knee 
and Hip Arthroplasty. J Arthroplasty. 2016; 31(11):2395-
2401. doi:10.1016/j.arth.2016.04.011.
5. Onochie E, Kayani B, Dawson-Bowling S, Millington S, Achan 
P, Hanna S. Total hip arthroplasty in patients with chronic 
liver disease: A systematic review. SICOT-J. 2019; 5:40. 
6. Nicoll A. Surgical risk in patients with cirrhosis. J 
Gastroenterol Hepatol. 2012; 27(10):1569-1575. 
7. Berstock JR, Beswick AD, Lenguerrand E, Whitehouse MR, 
Blom AW. Mortality after total hip replacement surgery. Bone 
Jt Res. 2014; 3(6):175-182. doi:10.1302/2046-
8. Hunt LP, Ben-Shlomo Y, Clark EM, et al. 90-day mortality after 
409,096 total hip replacements for osteoarthritis, from the 
National Joint Registry for England and Wales: a retrospective 
analysis. Lancet Lond Engl. 2013; 382(9898):1097-1104. 
9. Cram P, Lu X, Kaboli PJ, et al. Clinical characteristics and 
outcomes of Medicare patients undergoing total hip 
arthroplasty, 1991-2008. JAMA. 2011; 305(15):1560-1567. 
10. Hillerson D, Ogunbayo GO, Salih M, et al. Outcomes and 
Characteristics of Myocardial Infarction in Patients with 
Cirrhosis. J Invasive Cardiol. 2019; 31(7):E162-E169.
11. An J, Shim JH, Kim SO, et al. Prevalence and Prediction of 
Coronary Artery Disease in Patients with Liver Cirrhosis. 
Circulation. 2014; 130(16):1353-1362. 
12. Westerkamp AC, Lisman T, Porte RJ. How to minimize blood 
loss during liver surgery in patients with cirrhosis. HPB 
(Oxford). 2009; 11(6):453-458. doi:10.1111/j.1477-
13. Liu P, Hum J, Jou J, Scanlan RM, Shatzel J. Transfusion 
strategies in patients with cirrhosis. Eur J Haematol. 2020; 
104(1):15-25. doi:10.1111/ejh.13342.
14. Senzolo M, Sartori MT, Lisman T. Should we give 
thromboprophylaxis to patients with liver cirrhosis and 
coagulopathy? HPB (Oxford). 2009; 11(6):459-464. 
15. Anand AC. Nutrition and Muscle in Cirrhosis. J Clin Exp 
Hepatol. 2017; 7(4):340-357. doi:10.1016/j.jceh.2017.11.001.
16. Jiang SL, Schairer WW, Bozic KJ. Increased rates of 
periprosthetic joint infection in patients with cirrhosis 
undergoing total joint arthroplasty. Clin Orthop. 
2014; 472(8):2483-2491. doi:10.1007/s11999-014-3593-y.
17. McLawhorn AS, Buller LT. Bundled Payments in Total Joint 
Replacement: Keeping Our Care Affordable and High in 
Quality. Curr Rev Musculoskelet Med. 2017; 10(3):370-377.